Eli Lilly Shares Decline Over 4% as Structure Therapeutics Reports Positive Data for Experimental Weight-Loss Drug
Stock News
Mar 17
Eli Lilly (LLY.US) shares opened lower and extended losses on Tuesday, falling more than 4% to $948.76 at the time of writing. The decline follows news that Structure Therapeutics (GPCR.US) announced positive results for its experimental weight-loss drug, aleniglipron. Data showed that patients lost approximately 15% of their body weight after 44 weeks of treatment. BMO Capital Markets analyst Evan Seigerman noted that the drug's efficacy "appears highly competitive" and may even surpass similar oral medications from Novo Nordisk (NVO.US) and Eli Lilly. Structure Therapeutics plans to initiate late-stage studies in the second half of 2026, using a "low and slow" dose titration approach to mitigate gastrointestinal side effects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.